Coherus BioSciences Inc (NAS:CHRS)
$ 2.12 -0.11 (-4.93%) Market Cap: 240.62 Mil Enterprise Value: 616.20 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 42/100

Coherus BioSciences Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2023 / 04:15PM GMT
Release Date Price: $9.85 (+9.69%)
Christopher Thomas Schott
JPMorgan Chase & Co, Research Division - Senior Analyst

Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be introducing Coherus today. From the company, we have Denny Lanfear, President and CEO, who's going to make some opening remarks, and then we'll jump into a Q&A session with the broader management team after that. So with that, over to you, Denny.

Dennis M. Lanfear
Coherus BioSciences, Inc. - Chairman, President & CEO

Thank you, Chris, and thank you all for joining us today. Let me first apprise you of our forward-looking statements and direct you to the company's SEC filings. So I will try to remember to call out the slide numbers for those of you on the webcast since it's not concurrently broadcast. So today, I'm first going to talk a little bit and summarize the company's strategy. And then I'm going to talk about the ophthalmology franchise, which is evolving, our oncology franchise. I'll make a few comments about YUSIMRY, and then I'll focus a bit on the company's I-O franchise

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot